Global Hematology Diagnostics Market to Reach USD 5.6 Billion by 2026
By LabMedica International staff writers Posted on 22 Aug 2019 |
The global hematology diagnostics market is projected to grow at a CAGR of 5.0% from USD 3.50 billion in 2017 to USD 5.59 billion by 2026, driven by the growing occurrence of blood disorders and increased adoption of automated testing processes.
These are the latest findings of Transparency Market Research, (Albany, NY, USA), a global market intelligence company providing business information reports and services.
The WHO has declared that hemoglobin disorders are now substantially common among 89% of the births in 71% of countries. Nearly 1.1% of couples across the globe are at risk of giving birth to children with a hemoglobin disorder and around 2.7 of every 1,000 conceptions are affected by hemoglobin. Additionally, the WHO states that least 20% of the global population is a carrier of α+ thalassaemia. This high prevalence of hemoglobin disorders is fueling the growth of the global hematology diagnostics market.
Additionally, the growth of global hematology diagnostics market is being further driven by automation, which is the main focal point for hematology labs. The automation of hematology diagnostics processes has resulted in reduced turnaround time, which has sped up the treatment regimen for blood disorders in general. Several laboratories across the world are adopting automation for pre-analytical, analytical, and post analytical processes to standardize and improve the process.
Geographically, the global hematology diagnostics market is expected to be dominated by North America due to the growing prevalence of various types of blood diseases and presence of prominent market players in the region. Europe is the world’s second-largest hematology diagnostics market due to the growing importance of hematology research in the region. Additionally, Asia-Pacific is estimated to be one of the fastest growing regions in the global hematology diagnostics market due to the growing prevalence of genetic diseases and blood disorders in the region.
Related Links:
Transparency Market Research
These are the latest findings of Transparency Market Research, (Albany, NY, USA), a global market intelligence company providing business information reports and services.
The WHO has declared that hemoglobin disorders are now substantially common among 89% of the births in 71% of countries. Nearly 1.1% of couples across the globe are at risk of giving birth to children with a hemoglobin disorder and around 2.7 of every 1,000 conceptions are affected by hemoglobin. Additionally, the WHO states that least 20% of the global population is a carrier of α+ thalassaemia. This high prevalence of hemoglobin disorders is fueling the growth of the global hematology diagnostics market.
Additionally, the growth of global hematology diagnostics market is being further driven by automation, which is the main focal point for hematology labs. The automation of hematology diagnostics processes has resulted in reduced turnaround time, which has sped up the treatment regimen for blood disorders in general. Several laboratories across the world are adopting automation for pre-analytical, analytical, and post analytical processes to standardize and improve the process.
Geographically, the global hematology diagnostics market is expected to be dominated by North America due to the growing prevalence of various types of blood diseases and presence of prominent market players in the region. Europe is the world’s second-largest hematology diagnostics market due to the growing importance of hematology research in the region. Additionally, Asia-Pacific is estimated to be one of the fastest growing regions in the global hematology diagnostics market due to the growing prevalence of genetic diseases and blood disorders in the region.
Related Links:
Transparency Market Research
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus